Skip to main content
Download PDF

Potential association of rheumatic diseases with bone mineral density and fractures: a bi-directional mendelian randomization study

BMC Musculoskeletal Disorders volume 25, Article number: 521 (2024) Cite this article

Abstract

Background

Previous studies have implicated rheumatoid arthritis as an independent risk factor for bone density loss. However, whether there is a causal relationship between rheumatic diseases and bone mineral density (BMD) and fractures is still controversial. We employed a bidirectional Mendelian analysis to explore the causal relationship between rheumatic diseases and BMD or fractures.

Methods

The rheumatic diseases instrumental variables (IVs) were obtained from a large Genome-wide association study (GWAS) meta-analysis dataset of European descent. Analyses were performed for the three rheumatic diseases: ankylosing spondylitis (AS) (n = 22,647 cases, 99,962 single nucleotide polymorphisms [SNPs]), rheumatoid arthritis (RA) (n = 58,284 cases, 13,108,512 SNPs), and systemic lupus erythematosus (SLE) (n = 14,267 cases, 7,071,163 SNPs). Two-sample Mendelian randomization (MR) analyses were carried out by using R language TwoSampleMR version 0.5.7. The inverse-variance weighted (IVW), MR-Egger, and weighted median methods were used to analyze the causal relationship between rheumatic diseases and BMD or fracture.

Results

The MR results revealed that there was absence of evidence for causal effect of AS on BMD or fracture. However, there is a positive causal relationship of RA with fracture of femur (95% CI = 1.0001 to 1.077, p = 0.046), and RA and fracture of forearm (95% CI = 1.015 to 1.064, p = 0.001). SLE had positive causal links for fracture of forearm (95% CI = 1.004 to 1.051, p = 0.020). Additionally, increasing in heel bone mineral density (Heel-BMD) and total bone mineral density (Total-BMD) can lead to a reduced risk of AS without heterogeneity or pleiotropic effects. The results were stable and reliable. There was absence of evidence for causal effect of fracture on RA (95% CI = 0.929 to 1.106, p = 0.759), and fracture on SLE (95% CI = 0.793 to 1.589, p = 0.516).

Conclusions

RA and SLE are risk factors for fractures. On the other hand, BMD increasing can reduce risk of AS. Our results indicate that rheumatic diseases may lead to an increased risk of fractures, while increased BMD may lead to a reduced risk of rheumatic diseases. These findings provide insight into the risk of BMD and AS, identifying a potential predictor of AS risk as a reduction in BMD.

Peer Review reports

Introduction

Rheumatic diseases cover a variety of conditions that primarily affect the joints, bones, muscles, and connective tissues in the body [1, 2]. There are more than 100 different types of rheumatic diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), osteoarthritis, psoriatic arthropathy and inflammatory spondylitis and so on. They represent a variety of diseases with different characteristics. Various risk factors, including some controllable factors such as obesity and osteoporosis, are associated with the development of these rheumatic diseases [3,4,5]. Fracture is a common complication of rheumatic diseases. Rheumatic diseases have been reported to cause low bone mass with periarticular osteoporosis, malnutrition, and osteomalacia due to malabsorption [6]. Inflammatory rheumatic diseases, in particular, may lead to an increased risk of fractures [7, 8]. Rheumatic diseases in children, such as juvenile idiopathic arthritis, can affect the skeletal system, leading to reduced bone mineral density (BMD) and a high risk of fragility fractures in childhood [9].

Ankylosing spondylitis (AS) is a chronic autoimmune disease marked by persistent inflammation and the development of new bone in the central axial skeleton and sacroiliac joints [10, 11]. It also extends to peripheral joints and may involve extra-articular areas. These developments can lead to inflammatory low back pain and limitations in spinal mobility. Additionally, individuals with AS experience a decrease in BMD over the course of the disease. Research has consistently shown that BMD reduction is an early occurrence in the progression of ankylosing spondylitis [12]. Rheumatoid arthritis (RA) is an autoimmune disorder primarily targeting the joints. It manifests as chronic inflammation, resulting in joint pain, swelling, stiffness, and the erosion of joint tissues [13, 14]. This inflammatory cascade can also adversely affect bone health, including BMD. Numerous studies have demonstrated that RA is linked independently to a heightened risk of osteoporosis, leading to a significant increase in fracture risk and BMD decline [15, 16]. Systemic lupus erythematosus (SLE) is an autoimmune disease capable of impacting multiple organs and bodily systems, including the musculoskeletal system [17]. The connection between SLE and BMD is significant, as SLE can contribute to decreased BMD levels, elevating the risk of osteoporosis and fractures [18, 19]. SLE patients exhibited significantly lower BMD measurements at the lumbar spine and hip when compared to healthy controls matched for sex, age, and geographical location, and similar measurements to those of RA patients [18].

BMD is a metric employed to evaluate the mineral content in specific bone regions, commonly the spine, hip, or forearm. It provides an indication of bone density and strength, which are crucial for skeletal health [20]. Many rheumatic diseases can lead to a decline in bone density, heightening the susceptibility to osteoporosis and fractures [21, 22]. However, observational studies have limitations. They may not account for unmeasured or unknown confounding variables and typically cannot definitively establish a direct cause-and-effect relationship between exposure and outcome unless the study design meticulously ensures temporal and causal sequencing. In the context of most observational studies on BMD and rheumatic diseases, uncertainty persists regarding whether diminished BMD escalates the risk of developing the condition or if individuals with a rheumatic ailment are more predisposed to fractures. Additionally, it’s plausible that the connection between BMD and rheumatic conditions arises from an underlying lifestyle or environmental factor that elevates the risk for both conditions. So far, there is no conclusive evidence whether there is a causal relationship between rheumatic diseases and BMD or whether an increase in BMD can reduce the risk of rheumatic diseases.

Mendelian randomization (MR) is an approach used to probe causal relationships, effectively sidestepping the aforementioned limitations by employing genetic variants as exposure instruments [23, 24]. Recently, an MR study was used to explore the causality between AS and osteoporosis [12]. In the present study, we utilized data from publicly available genome-wide association studies (GWAS) to investigate the causal relationship between rheumatic diseases (AS, RA, and SLE) and BMD or fracture. The initial phase involved examining whether AS, RA, and SLE exert causal effects on BMD measurements or fracture. Subsequently, in the second phase, we assessed whether BMD measurements or fracture are causally linked with AS, RA, and SLE.

Materials and methods

Study design

The assumptions underlying the MR analysis of the causal relationship between rheumatic diseases and BMD or fracture include: Assumption 1: The selected single nucleotide polymorphisms (SNPs) should exhibit a robust correlation with the exposure; Assumption 2: The selected SNPs should not be associated with the outcome through confounding variables; Assumption 3: The selected SNPs are anticipated to influence outcomes through exposure, rather than through a direct association (Fig. 1). All data utilized in this study were sourced from publicly available databases or pre-existing publications, obviating the need for additional ethical approval.

Fig. 1
figure 1

The schematic diagram of Mendelian randomization (MR). Three assumptions should be met, as follows: Assumption 1: The SNPs should be closely related to exposures; Assumption 2: The IVs selected are supposed to be independent of confounders; Assumption 3: SNPs should　influence the outcomes just through the exposure. (IVs, instrumental variables; SNPs, single-nucleotide polymorphisms)

Full size image

Data sources

Data for the two-way MR analysis were obtained from the Genome-Wide Association Study (GWAS) database (https://gwas.mrcieu.ac.uk/). Instrumental variables for rheumatic diseases were as follows: AS included 22,647 samples (number of cases: 9,069, number of controls: 1,550) from Europe with a total of 99,962 SNPs; RA included 58,284 samples (number of cases: 14,361, number of controls: 43,923) from Europe with a total of 13,108,512 SNPs; SLE included 14,267 samples (number of cases: 5,201, number of controls: 9,066) from Europe with a total of 7,071,163 SNPs. BMD data encompassed measurements for the total bone density and heel bone density sourced from the GWAS database [12]. Specifically, the sample sizes for each category were as follows: whole body: 56,284 samples with a total of 16,162,733 SNPs; heel: 265,627 samples with a total of 9,851,867 SNPs. Fracture data included occurrences in the femur, pelvis, lumbar spine, and forearm, obtained from the GWAS database [25]. Sample sizes for each category were as follows: forearm: 215,724 samples (number of cases: 9,956, number of controls: 205,768) with a total of 16,380,460 SNPs; femur: 215,443 samples (number of cases: 3,983, number of controls: 211,460) with a total of 16,380,458 SNPs; lumbar spine and pelvis: 215,698 samples (number of cases: 2,859, number of controls: 212,839) with a total of 16,380,457 SNPs (Supplementary Table 1).

Analytical method

Mendelian randomization analysis was conducted using the R programming language, specifically with the TwoSampleMR package version 0.5.7. In this two-sample MR analysis, genome-wide significant SNPs (with P < 5 × 10− 8) were employed as instrumental variables to investigate the causal impacts of AS, RA, and SLE on BMD and fracture risk. To mitigate the influence of linkage disequilibrium, a clumping process (R2 < 0.001, window size = 10,000 kb) [26] was applied to the European samples from the 1000 Genomes Project. This study utilized multiple methods including inverse variance weighted (IVW), weighted median, MR-Egger, and weighted mode approaches to delve into the causal relationships between AS, RA, and SLE, and BMD or fracture risk. The MR Egger regression intercept was employed to assess pleiotropy.

Statistical analyses

This study adopted the IVW, weighted median, MR-Egger, and weighted mode methods to explore the causal relationships between AS, RA, and SLE and BMD or fractures. The MR Egger regression intercept was used to evaluate pleiotropy, and when p > 0.05, it was considered that there was no pleiotropy. Heterogeneity was assessed using Cochrane’s Q statistic, and Q_pval > 0.05 was considered to have no heterogeneity. Positive results ensured that IVW was statistically significant (p < 0.05), and that the β directions of IVW, MR Egger, and Weighted median were consistent. Positive results at least ensure that IVW is significant (p < 0.05), and the β directions of IVW, MR Egger, and Weighted median are consistent.

In addressing the multiplicity of hypothesis tests conducted within our study, we implemented rigorous statistical correction methods to control the risk of Type I errors. Specifically, we applied both the Bonferroni correction and the Benjamini-Hochberg false discovery rate (FDR) controlling procedure. The Bonferroni correction was utilized to adjust the significance thresholds for each individual test, setting the corrected alpha at alpha = 0.05/number of tests, which stringently controls the family-wise error rate. Concurrently, the Benjamini-Hochberg procedure was employed to control the FDR, offering a balance between discovery and error rate, which is particularly advantageous in studies with a high number of simultaneous hypothesis tests.

Results

Casual relationship between AS and BMD or fractures

To assess the potential causal impact of rheumatic diseases on BMD and fracture risk, we first examined the casual relationship between AS and BMD or fractures by a two-sample MR analysis. In our study, we included 23–25 independent single nucleotide polymorphisms (SNPs) as instrumental variables (IVs) for AS. The results from weighted median, IVW, and MR-Egger regression tests collectively indicate that there is no significant association between AS and either BMD or fractures (Table 1).

Table 1 The Mendelian randomization (MR) analysis results of AS on fracture of forearm, fracture of femur, fracture of lumbar spine and pelvis, Heel-BMD and Total-BMD.
Full size table

Then we examined various BMD measures including heel bone mineral density (Heel-BMD) and total bone mineral density (Total-BMD), utilizing them as exposures in a two-sample Mendelian randomization analysis for AS. Our analysis indicated a positive causal effect of Heel-BMD and AS (95% CI = 0.795 to 0.971, p = 0.012), and Total-BMD and AS (95% CI = 0.907 to 0.990, p = 0.017), as shown in Table 2.

Table 2 Causal effects of BMD (Heel-BMD, Total-BMD) on AS.
Full size table

To further clarify the correlation between Heel-BMD, Total-BMD, and AS, we conducted scatter plot analyses. Figure 2 demonstrate a negative correlation between Heel-BMD and AS (Fig. 2A), as well as Total-BMD and AS (Fig. 2B). These results suggest that an increase in Heel-BMD, and Total-BMD lead to a reduced risk of AS. Notably, no heterogeneity or pleiotropy was observed in these findings.

Fig. 2
figure 2

The scatter plot for MR analyses of causal associations between rheumatic diseases AS and BMD. (A) The scatter plot of the relationship between Heel-BMD and AS. (B) The scatter plot of the relationship between Total-BMD and AS.

Full size image

Casual relationship between RA and BMD or fractures

The MR results for RA with respect to BMD or fractures are displayed in Table 3. Cochran’s Q test showed the absence of heterogeneity and pleiotropy. Therefore, we adopted an IVW method to assess the causal relationship between RA and BMD or fracture risk [27, 28]. As shown in Table 3, the results showed a positive causal association between RA and fractures of the femur (95% CI = 1.0001 to 1.077, p = 0.046), as well as RA and fractures of the forearm (95% CI = 1.015 to 1.064, p < 0.01). These results suggest that RA can lead to an increased risk of both femur and forearm fractures without heterogeneity or pleiotropic effects. However, as shown in Table 4, there was absence of evidence for causal connection between fracture of forearm and RA (95% CI = 0.929–1.106, p = 0.759). To further elucidate the association between RA and fractures, we conducted a scatter plot analysis. As depicted in Fig. 3A and B, the slope of the scatter plot (β value) is greater than 0, suggesting that RA may elevate the risk of both femur and forearm fractures (Fig. 3).

Table 3 The Mendelian randomization (MR) analysis results of RA on fracture of forearm, fracture of femur, fracture of lumbar spine and pelvis, Heel-BMD and Total-BMD.
Full size table
Table 4 Causal effects of fracture of forearm and BMD (Heel-BMD, Total-BMD) on RA.
Full size table
Fig. 3
figure 3

The scatter plot for MR analyses of causal associations between rheumatic diseases RA and fractures. (A) The scatter plot of the relationship between RA and fracture of femur. (B) The scatter plot of the relationship between RA and fracture of forearm

Full size image

Casual relationship between SLE and BMD or fractures

In addition, the correlation between SLE and BMD or fracture risk was also investigated as shown in Table 5. Based on our results, SLE exhibited a positive causal association with fracture of forearm (95% CI = 1.002 to 1.057, p = 0.034), suggesting that SLE can lead to an increased risk of fracture of forearm with significant heterogeneity and no pleiotropic effect (Table 5). Additionally, there was absence of evidence for causal connection between fracture of forearm and SLE (95% CI = 0.793–1.159, p = 0.516) (Table 6). Further scatter plot analysis demonstrates that SLE may also increase the risk of fracture of femur and fracture of forearm (Fig. 4).

Table 5 The Mendelian randomization (MR) analysis results used inverse variance weighted (IVW), MR-Egger, and weighted median methods showing causal effect of SLE on fracture of forearm, fracture of femur, fracture of lumbar spine and pelvis, Heel-BMD and Total-BMD.
Full size table
Table 6 Causal effects of fracture of forearm and BMD (Heel-BMD, Total-BMD) on SLE.
Full size table
Fig. 4
figure 4

The scatter plot for MR analyses of causal associations between rheumatic diseases SLE and fracture of forearm

Full size image

Discussion

This study employed extensive GWAS data from publicly available databases and conducted an unbiased two-sample MR analysis to investigate the causal associations between rheumatic diseases, BMD, and fracture risk. Following rigorous quality control measures, we obtained the following results: (1) There is no significant causal relationship between AS and either BMD or fracture risk; (2) RA may lead to an increased risk of fracture of femur and fracture of forearm, with no heterogeneity or multiplicity; (3) SLE may lead to an increased risk of fracture of forearm, with significant heterogeneity and no pleiotropic effects; (4) Higher Heel-BMD and Total-BMD are linked to a reduced risk of AS, without heterogeneity or pleiotropic effects; (5) There is no significant relationship between fractures and rheumatic diseases. This study found that RA and SLE can lead to an increased risk of fractures, while increased Heel-BMD and Total-BMD can lead to a reduced risk of AS. These findings provide new evidence for the treatment and prevention of clinical rheumatic diseases.

The relationship between rheumatic diseases and BMD is intricate and affected by multiple factors. AS, RA and SLE are autoimmune diseases, and osteoporosis has been recognized as a common additional manifestation in individuals with AS, RA, and SLE [21, 29,30,31,32]. Numerous studies have demonstrated that patients with AS [33,34,35], RA [36, 37], and SLE [19, 38] tend to have significantly lower BMD. However, whether there is a causal relationship between rheumatoid arthritis and BMD remains unclear. In the present study, we revealed that an increase in BMD including Heel-BMD and Total-BMD contributes to a diminished risk of AS without the presence of heterogeneity or pleiotropic effects. A recent study by Karberg et al., also reached conclusions consistent with our results. They encompassed 103 AS patients and found that bone loss was more prevalent in AS patients with syndesmotic osteophytes [39].

In addition, there are many studies on the impact of rheumatic diseases on fractures. A cohort study examining long-term fracture risk in rheumatoid arthritis over a 10-year period showed that RA-specific risk factors are important for future development of severe fragility fractures [8]. Another study based on current literature showed that childhood rheumatic disease is associated with reduced BMD and increased vertebral and nonvertebral fractures [40]. Here, we found that RA and SLE could elevate the risk of fracture of forearm. In a population-based cross-sectional study, the detection rate of self-reported vertebral fractures increased from 6.4 to 18.9% in women with RA and/or SLE, suggesting that RA and SLE contribute to fracture risk increase [41]. Our results, together with these previous findings, provide some theoretical basis for the clinical treatment of patients with RA or SLE, and doctors can implement necessary preventive measures to reduce the risk of fractures.

This study has the following innovations: (1) The investigation commences by delving into molecular mechanisms, employing rheumatic diseases as primary exposure factors, and scrutinizing the causal interplay between rheumatic diseases, BMD, and fracture risk. This approach is underpinned by robust theoretical foundations and holds significant clinical relevance. (2) Rigorous quality control measures and analytical techniques were applied in this study, employing a diverse set of models to assess causal effects. As a result, the research outcomes are both dependable and consistent. (3) In contrast to prior MR studies that typically focus on single exposure factors, this study encompasses three distinct, prototypical rheumatic diseases. This presented a considerable workload and analytical complexity, setting it apart in terms of scope and challenge from previous MR investigations.

This study has its own set of limitations: (1) The GWAS data for rheumatic diseases are derived exclusively from European populations. Consequently, the findings may not be extrapolated to other races and regions. More comprehensive studies are warranted among diverse ethnic groups; (2) Despite leveraging the largest available large-scale GWAS data, subsequent research endeavors should focus on further augmenting the sample size to yield more precise assessments. (3) The large number of SNPs used, while enhancing instrumental strength, does not fully preclude the risk of pleiotropy or violation of instrumental variable assumptions. (4) The multiple testing corrections applied might not completely eliminate the risk of Type I or II errors, particularly for small effect sizes. Therefore, findings should be interpreted with caution, keeping in mind the potential for both false positives and negatives, and the need for replication in more diverse populations to confirm these causal inferences.

Conclusions

We utilized a two-sample MR approach to explore potential causal relationships between rheumatic diseases and BMD or fracture risk. Our analysis showed that RA and SLE are associated with an increased risk of fracture. Increased heel BMD and total BMD are associated with decreased risk of AS. In contrast, there was no significant relationship between fractures and rheumatic diseases. These insights shed light on the relationship between BMD and rheumatic diseases, highlighting that increased BMD may reduce the risk of developing AS.

Data availability

The data used to support the findings of this study are available from the corresponding author upon request.

References

  1. Onuora S. Rheumatic diseases on the rise. Nat Rev Rheumatol. 2023;19:396.

    Article  PubMed  Google Scholar 

  2. Hurd K, Barnabe C. Systematic review of rheumatic disease phenotypes and outcomes in the indigenous populations of Canada, the USA, Australia and New Zealand. Rheumatol Int. 2017;37:503–21.

    Article  PubMed  Google Scholar 

  3. Maruotti N, Corrado A, Cantatore FP. Osteoporosis and rheumatic diseases. Reumatismo. 2014;66:125–35.

    Article  CAS  PubMed  Google Scholar 

  4. Dubrovsky AM, Lim MJ, Lane NE. Osteoporosis in Rheumatic Diseases: anti-rheumatic drugs and the Skeleton. Calcif Tissue Int. 2018;102:607–18.

    Article  CAS  PubMed  Google Scholar 

  5. Gremese E, Tolusso B, Gigante MR, Ferraccioli G. Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). Front Immunol. 2014;5:576.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Sobh MM, Abdalbary M, Elnagar S, Nagy E, Elshabrawy N, Abdelsalam M, Asadipooya K, El-Husseini A. Secondary osteoporosis and metabolic bone diseases. J Clin Med. 2022;11.

  7. Weiss RJ, Wick MC, Ackermann PW, Montgomery SM. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases -- a case-control study with 53,108 patients with fracture. J Rheumatol. 2010;37:2247–50.

    Article  PubMed  Google Scholar 

  8. Ajeganova S, Andersson M, Forslind K, Gjertsson I, Nyhall-Wahlin BM, Svensson B, Hafstrom I. Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody positivity and glucocorticoids. A cohort study over 10 years. BMC Rheumatol. 2023;7:23.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Di Marcello F, Di Donato G, d’Angelo DM, Breda L, Chiarelli F. Bone Health in Children with Rheumatic disorders: Focus on Molecular mechanisms, diagnosis, and management. Int J Mol Sci. 2022;23.

  10. Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, Qiu G, Cao X, Weng X. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7:22.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: a systematic literature review. Clin Rheumatol. 2021;40:3079–93.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Mei J, Hu H, Ding H, Huang Y, Zhang W, Chen X, Fang X. Investigating the causal relationship between ankylosing spondylitis and osteoporosis in the European population: a bidirectional mendelian randomization study. Front Immunol. 2023;14:1163258.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Med Princ Pract. 2018;27:501–7.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gravallese EM, Firestein GS. Rheumatoid arthritis - common origins, divergent mechanisms. N Engl J Med. 2023;388:529–42.

    Article  CAS  PubMed  Google Scholar 

  15. Moshayedi S, Tasorian B, Almasi-Hashiani A. The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis. Sci Rep. 2022;12:15844.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Theander L, Willim M, Nilsson JA, Karlsson M, Akesson KE, Jacobsson LTH, Turesson C. Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis. RMD Open. 2020;6.

  17. Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, Zeb S, Tariq MA, Patlolla SR, Ali J, Hashim SN, Hashim S. An overview of systemic Lupus Erythematosus (SLE) Pathogenesis, classification, and management. Cureus. 2022;14:e30330.

    PubMed  PubMed Central  Google Scholar 

  18. Gilboe IM, Kvien TK, Haugeberg G, Husby G. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis. 2000;59:110–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Boone JB, Wheless L, Camai A, Tanner SB, Barnado A. Low prevalence of bone mineral density testing in patients with systemic lupus erythematosus and glucocorticoid exposure. Lupus. 2021;30:403–11.

    Article  CAS  PubMed  Google Scholar 

  20. van der Burgh AC, de Keyser CE, Zillikens MC, Stricker BH. The effects of osteoporotic and non-osteoporotic medications on fracture risk and bone Mineral Density. Drugs. 2021;81:1831–58.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kareem R, Botleroo RA, Bhandari R, Ogeyingbo OD, Ahmed R, Gyawali M, Venkatesan N, Elshaikh AO. The impact of rheumatoid arthritis on bone loss: links to osteoporosis and Osteopenia. Cureus. 2021;13:e17519.

    PubMed  PubMed Central  Google Scholar 

  22. Adami G, Fassio A, Rossini M, Caimmi C, Giollo A, Orsolini G, Viapiana O, Gatti D. Osteoporosis in Rheumatic diseases. Int J Mol Sci. 2019;20.

  23. Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafo MR, Palmer T, Schooling CM, Wallace C, Zhao Q, Smith GD. Mendelian randomization. Nat Rev Methods Primers. 2022;2.

  24. Rees JMB, Foley CN, Burgess S. Factorial mendelian randomization: using genetic variants to assess interactions. Int J Epidemiol. 2020;49:1147–58.

    Article  PubMed  Google Scholar 

  25. Tang Y, Zhang L, Ye D, Zhao A, Liu Y, Zhang M. Causal relationship between type 1 diabetes and osteoporosis and fracture occurrence: a two-sample mendelian randomization analysis. Osteoporos Int. 2023;34:1111–7.

    Article  CAS  PubMed  Google Scholar 

  26. Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061–73.

    Article  Google Scholar 

  27. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data mendelian randomization. Stat Med. 2017;36:1783–802.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP, Kutalik Z, Holmes MV, Minelli C, Morrison JV, Pan W, Relton CL, Theodoratou E. Guidelines for performing mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019;4:186.

    Article  PubMed  Google Scholar 

  29. Klingberg E, Lorentzon M, Mellstrom D, Geijer M, Gothlin J, Hilme E, Hedberg M, Carlsten H. Forsblad-d’elia H. osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis Res Ther. 2012;14:R108.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kim Y, Kim GT. Positive Effects of Biologics on osteoporosis in rheumatoid arthritis. J Rheum Dis. 2023;30:3–17.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sen D, Keen RW. Osteoporosis in systemic lupus erythematosus: prevention and treatment. Lupus. 2001;10:227–32.

    Article  CAS  PubMed  Google Scholar 

  32. Jung JY, Choi ST, Park SH, Kwon SR, Kim HA, Kim SS, Kim SH, Suh CH. Prevalence of osteoporosis in patients with systemic lupus erythematosus: a multicenter comparative study of the World Health Organization and fracture risk assessment tool criteria. Osteoporos Sarcopenia. 2020;6:173–8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol. 2012;31:1529–35.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Pray C, Feroz NI, Nigil Haroon N. Bone Mineral density and fracture risk in Ankylosing spondylitis: a Meta-analysis. Calcif Tissue Int. 2017;101:182–92.

    Article  CAS  PubMed  Google Scholar 

  35. Ulu MA, Cevik R, Dilek B. Comparison of PA spine, lateral spine, and femoral BMD measurements to determine bone loss in ankylosing spondylitis. Rheumatol Int. 2013;33:1705–11.

    Article  PubMed  Google Scholar 

  36. Kinjo M, Setoguchi S, Solomon DH. Bone mineral density in older adult patients with rheumatoid arthritis: an analysis of NHANES III. J Rheumatol. 2007;34:1971–5.

    CAS  PubMed  Google Scholar 

  37. Haugeberg G, Strand A, Kvien TK, Kirwan JR. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med. 2005;165:1293–7.

    Article  PubMed  Google Scholar 

  38. Chanakul A, Khunrattanaphon S, Deekajorndech T. Low bone mineral density in Thai children with systemic lupus erythematosus: prevalence and risk factors. Asian Biomed (Res Rev News). 2021;15:245–50.

    Article  PubMed  Google Scholar 

  39. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol. 2005;32:1290–8.

    PubMed  Google Scholar 

  40. Huber AM, Ward LM. The impact of underlying disease on fracture risk and bone mineral density in children with rheumatic disorders: a review of current literature. Semin Arthritis Rheum. 2016;46:49–63.

    Article  PubMed  Google Scholar 

  41. Rentero ML, Amigo E, Chozas N, Fernandez Prada M, Silva-Fernandez L, Abad Hernandez MA, Rodriguez Barrera JM, del Pino-Montes J, group Gs. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy. BMC Musculoskelet Disord. 2015;16:300.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This research received no external funding.

Author information

Authors and Affiliations

  1. Department of Orthopaedics, The Affiliated Cangnan Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325899, China

    Chen-xuan Hong & Feng-bo Dai

  2. Department of Orthopaedics, The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China

    Yan-zheng Pan

Authors
  1. Chen-xuan Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan-zheng Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feng-bo Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Chen-xuan Hong concept and design the study. Yan-zheng Pan collected and analyzed the data. Feng-bo Dai drafted the paper. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Feng-bo Dai.

Ethics declarations

Ethics approval and consent to participate

All data utilized in this study were sourced from publicly available databases or pre-existing publications, obviating the need for additional ethical approval.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hong, Cx., Pan, Yz. & Dai, Fb. Potential association of rheumatic diseases with bone mineral density and fractures: a bi-directional mendelian randomization study. BMC Musculoskelet Disord 25, 521 (2024). https://doi.org/10.1186/s12891-024-07496-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12891-024-07496-w

Keywords

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us